Publication
“AI and sustainability - cure or curse?”
While AI can help resolve data issues in sustainable investing, it can create problems such as information breaches and inherent bias in data.
Global | Publication | May 2017
Treaty/Act: CETA/Bill C-30 (An Act to implement the Comprehensive Economic and Trade Agreement between Canada and the European Union and its Member States and to provide for certain other measures)
Date: May 11, 2017 – Bill C-30 passes third reading in Senate
The overhaul to Canada’s pharmaceutical patent regime is nearly here. On May 11, 2017, the Canadian Senate passed Bill C-30 (the act intended to implement CETA into Canadian law) without amendment, the final major stage of the legislative process. Bill C-30 will become law once it receives royal assent, a formality.
As we reported, CETA and Bill C-30 provide key reforms to the Patent Act affecting the pharmaceutical industry, including:
We anticipate the details to be published shortly.
Are you CETA ready? Contact Norton Rose Fulbright with all your CETA questions.
Bill C-30, Third Reading (House of Commons)
Text of the final Comprehensive Economic and Trade Agreement
Publication
While AI can help resolve data issues in sustainable investing, it can create problems such as information breaches and inherent bias in data.
Publication
With the Court of Final Appeal (CFA) decision of Tam Sze Leung & Ors v Commissioner of Police [2024] HKCFA 8 being handed down on 10 April 2024, the legality and constitutionality of the use of “Letters of No Consent” (LNCs) by the Police has been finally confirmed.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023